18 articles
Moderna and Merck announced a breakthrough in mRNA cancer vaccine collaboration, marking the first late-stage success after over a century of failures. The vaccine showed efficacy in melanoma patients
Asian stocks edged lower ahead of Fed Chair Warsh's Jackson Hole speech, while US crude oil rose on Strait of Hormuz tensions. Moderna announced a $2 billion fundraising plan to fund cancer vaccine de
Oil prices fell below $90 per barrel amid escalating U.S.-Canada trade tensions, driving Treasury yields lower. Global markets rallied on the news, though energy sectors faced declines while pharma st
Moderna and Merck announced positive data for their combination mRNA cancer vaccine intismeran and Keytruda in melanoma patients. The companies plan to present detailed study results at an upcoming in
The U.S. Treasury doubled bond buybacks to stabilize debt markets, while Moderna and Merck surged on a cancer vaccine breakthrough. Middle East conflicts reduced refining capacity, driving European di
Asian stocks are set to rebound following US Treasury plans to boost bond buybacks, while commodities like oil and gold saw gains. Corporate highlights include Moderna and Merck's successful melanoma
Moderna and Merck reported positive Phase III trial results for a personalized mRNA melanoma vaccine, cutting recurrence risk by half. This breakthrough validates mRNA technology for oncology, with fu
Moderna and Merck announced successful late-stage trial results for their combined melanoma treatment, reducing cancer recurrence and spread. Following the data, Moderna shares surged 60% while Merck
Moderna shares surged over 60% after its vaccine combined with Merck's Keytruda met late-stage trial goals, while Brent crude hit a three-week high amid Middle East tensions. U.S. stock futures remain
Moderna and Merck announced that a personalized mRNA vaccine combined with Keytruda successfully slowed melanoma recurrence in late-stage trials. Detailed data will be presented at an upcoming medical
The FDA approved Moderna's mFLUSIVA, the first mRNA-based influenza vaccine, for US adults aged 50 and older in the 2026–27 flu season. This milestone marks a key modernization step in vaccine develop
Moderna launched its first human trial for an experimental mRNA vaccine against the Bundibugyo Ebola strain, backed by a $50 million CEPI partnership. The study enrolls 80 volunteers in Canada amid a
Moderna CEO Stephane Bancel expressed interest in acquiring BioNTech's planned-to-close German production facilities, citing them as a cost-effective alternative to new builds pending government partn
US FDA staff indicated Moderna's mFlusiva flu shot data supports effectiveness in adults 65+. An advisory committee votes June 18 on approval for ages 50+, potentially making it the first mRNA seasona
Moderna secured up to $50 million from CEPI to develop a vaccine against the Bundibugyo ebolavirus strain amid an ongoing outbreak in the Democratic Republic of Congo. Additional funding from Gavi and
CureVac sued Moderna in Delaware federal court, alleging patent infringement on its mRNA vaccine technology and requesting royalties. This lawsuit adds to a wave of high-stakes intellectual property d
Syngenta halts paraquat production and Moderna settles a lipid patent dispute, while Middle East geopolitical tensions threaten Gulf supplies of LNG, urea, and polyethylene derivatives.
The FDA reversed course to review Moderna’s mRNA flu vaccine under an amended pathway, splitting approval requests by age group. Full approval is sought for ages 50–64, while adults 65+ face accelerat
ChemBrief